Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | MET | P08581 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2968713 | 0.84 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTHPGDLMNA | |
| SCHEMBL13240856 | 0.84 | KDM4E (0.43) | ALDH1A1KDM4EMAPTHPGDPTGS2 | |
| SCHEMBL15941095 | 0.82 | POLB (0.52) | ALDH1A1KDM4EMAPTHPGDMET | |
| SCHEMBL14074040 | 0.80 | PTGS2 (0.62) | ALDH1A1KDM4EMAPTHPGDPTGS2 | |
| SCHEMBL9472059 | 0.80 | ALDH1A1 (0.56) | ALDH1A1KDM4EMAPTHPGDPTGS2 | |
| SCHEMBL6133942 | 0.80 | ALDH1A1 (0.56) | ALDH1A1KDM4EMAPTHPGDPTGS2 | |
| SCHEMBL18745569 | 0.79 | PDE4B (0.45) | ALDH1A1KDM4EMAPTHPGDPTGS2 | |
| SCHEMBL11140135 | 0.79 | POLB (0.74) | ALDH1A1KDM4EMAPTHPGDPDE4A | |
| SCHEMBL6376456 | 0.79 | ALDH1A1 (0.55) | ALDH1A1KDM4EMAPTHPGDPTGS2 | |
| SCHEMBL2970930 | 0.78 | ALDH1A1 (0.47) | ALDH1A1LMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2935253-B1 | NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD (CA) | 2018-08-01 | — | — | EP | disclosed |
| US-9861637-B2 | Heterocyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2018-01-09 | — | — | US | disclosed |
| US-9861637-B2 | Heterocyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2018-01-09 | — | — | US | disclosed |
| US-20170143731-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. | 2017-05-25 | — | — | US | disclosed |
| US-20170143731-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. | 2017-05-25 | — | — | US | disclosed |
| US-20170143731-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS LTD. | 2017-05-25 | — | — | US | disclosed |
| US-9598367-B2 | Heterocyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-03-21 | — | — | US | disclosed |
| US-9598367-B2 | Heterocyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-03-21 | — | — | US | disclosed |
| US-9598367-B2 | Heterocyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-03-21 | — | — | US | disclosed |
| US-20160130228-A1 | Novel Heterocyclic Compounds as Bromodomain Inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2016-05-12 | — | — | US | disclosed |
| CN-101835755-A | Novel kinase inhibitors | HOFFMANN LA ROCHE | 2010-09-15 | — | — | CN | disclosed |
| US-7763617-B2 | Pyrazolopyridine-4-yl pyridazinone derivatives and addition salts thereof, and PDE inhibitors comprising the same derivatives or salts as active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-27 | — | — | US | disclosed |
| US-7763617-B2 | Pyrazolopyridine-4-yl pyridazinone derivatives and addition salts thereof, and PDE inhibitors comprising the same derivatives or salts as active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-27 | — | — | US | disclosed |
| US-7763617-B2 | Pyrazolopyridine-4-yl pyridazinone derivatives and addition salts thereof, and PDE inhibitors comprising the same derivatives or salts as active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-27 | — | — | US | disclosed |
| EP-2205564-A1 | NOVEL KINASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009053269-A1 | NOVEL KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| US-20090105209-A1 | BTK protein kinase inhibitors | ROCHE PALO ALTO LLC | 2009-04-23 | — | — | US | disclosed |
| US-20080207902-A1 | Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080207902-A1 | Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
| US-20080207902-A1 | Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130228-A1 | Novel Heterocyclic Compounds as Bromodomain Inhibitors | BRD4, BRDT, BRD3 | ALDH1A1 4346/4885KDM4E 385/4885MAPT 2581/4885 |
| US-20170143731-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRDT, BRD3 | ALDH1A1 4346/4885KDM4E 385/4885MAPT 2581/4885 |
| US-20090105209-A1 | BTK protein kinase inhibitors | BTK, SYK, LYN | ALDH1A1 3990/4885KDM4E 1225/4885MAPT 3889/4885 |
| US-20080207902-A1 | Pyrazolopyridine-4-Yl Pyridazinone Derivatives and Addition Salts Thereof, and Pde Inhibitors Comprising the Same Derivatives or Salts as Active Ingredient | PDE5A, PDE3A, PDE3B | ALDH1A1 215/4885KDM4E 436/4885MAPT 3621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.